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MaBACKGROUND Mitral regurgitation (MR) is the most common valvular heart disease, and mitral valve surgery is the
gold standard therapy for severe MR. Many patients with severe MR are not referred for surgery because of old age,
comorbidities, or severe left ventricular dysfunction. Transcatheter mitral valve implantation may be a better therapeutic
option for these high-risk patients with severe symptomatic MR.
OBJECTIVES This study sought to describe the ﬁrst-in-man series of transapical mitral valve implantation for mitral
regurgitation with the TIARA device.
METHODS Extensive preclinical ex vivo and animal studies were conducted with the transapical mitral valve implan-
tation of the Tiara system. The ﬁrst 2 cases of human implantation were successfully performed in a 73-year-old man and
a 61-year-old woman with severe functional MR. Both patients were in New York Heart Association class IV heart failure
with depressed left ventricular ejection fraction, pulmonary hypertension, and additional comorbidities.
RESULTS The valve was implanted uneventfully in both patients. General anesthesia and transapical access were
used. Patients were hemodynamically stable with no need for cardiopulmonary bypass. Immediately after implantation,
systemic arterial pressure and stroke volume increased and pulmonary pressure decreased dramatically. There were no
intraoperative complications, and both patients were extubated in the operating room. Post-procedural echocardiograms
at 48 h, 1 month, and 2 months demonstrated excellent prosthetic valve function with a low transvalvular gradient and
no left ventricular outﬂow tract obstruction. There was a trivial paravalvular leak in the ﬁrst patient at 48 h, which was
completely resolved at subsequent studies; no paravalvular leak occurred in the second patient.
CONCLUSIONS Transapical transcatheter mitral valve implantation is technically feasible and can be performed
safely. Early hemodynamic performance of the prosthesis was excellent. Transcatheter mitral valve implantation may
become an important treatment option for patients with severe MR who are at high operative risk. (J Am Coll Cardiol
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AB BR E V I A T I O N S
AND ACRONYM S
LV = left ventricular
LVOT = left ventricular
outﬂow tract
MR = mitral regurgitation
PVL = paravalvular leakage
TAMI = transapical mitral
valve implantation
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
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1815transcatheter mitral valve therapies is driven by pre-
clusion of high-risk patients from surgical mitral
valve repair or replacement. Percutaneous mitral
valve repair therapy with the MitraClip (Abbott Labo-
ratory, Abbott Park, Illinois) has been well studied
and is becoming an established option for a subset
of patients with MR (3–6); however, secondary to
various anatomical restrictions, many patients are
not candidates. Novel catheter-based technologies
intended to treat mitral valve disease percutaneously
or minimally invasively without the aid of cardiopul-
monary bypass are currently under development (7–
10). Transcatheter aortic valve replacement (TAVR)
has revolutionized the management of valvular aortic
stenosis by providing a safe and efﬁcacious alterna-
tive to surgical valve replacement. TAVR is currently
reserved for patients with severe aortic stenosis who
are at high risk for surgical valve replacement due
to comorbid conditions, thus increasing their opera-
tive risk for major complications and death. Conse-
quently, an explosive adoption of TAVR has
occurred (11–13). It is reasonable to suggest that the
next “revolution” may take place in the ﬁeld of trans-
catheter therapies for patients with severe MR and at
high surgical risk.SEE PAGE 1820
FIGURE 1 Transcatheter Mitral Valve Prosthesis
and Delivery System
(A) Atrial view of the transcatheter mitral valve prosthesis.
(B) Lateral proﬁle of the transcatheter mitral valve prosthesis.The structure and function of the mitral valve
are far more complex than the aortic valve. This
complexity poses many barriers to the development
of transcatheter mitral therapies: a D-shaped annu-
lus; the lack of a ﬁbrous annular structure; variability
of leaﬂet and subvalvular apparatus anatomy; and
proximity to the left ventricular outﬂow tract (LVOT),
circumﬂex coronary artery, and coronary sinus (14).
The transapical mitral valve implantation (TAMI)
of the Tiara system (Neovasc Inc., Richmond, British
Columbia, Canada) is a novel, catheter-based tech-
nology for the treatment of severe MR, with pub-
lished data from preclinical ex vivo, animal, and
cadaveric experiments (15,16). The present article
reports the ﬁrst 2 cases of human transcatheter TAMI.
TAMI SYSTEM
The Tiara valve consists of a nitinol alloy–based, self-
expanding frame and tri-leaﬂet bovine pericardium
(Figures 1A and B). The valve is anatomically shaped
to ﬁt the asymmetric, D-shaped mitral annulus. Its
atrial portion is designed to help seat the prosthesis
onto the atrial portion of the mitral valve annulus.
Ventricular anchoring structures are designed to
secure the valve onto the ﬁbrous trigons and poste-
rior shelf of the annulus. These features ﬁrmly securethe valve, preventing migration and mini-
mizing paravalvular leakage (PVL), LVOT
obstruction, and coronary vessel encroach-
ment. The valve is loaded into a 32-F delivery
device just before the procedure. The de-
livery device comprises a self-dilating tip
with a turn-knob mechanism and is designed
to directly enter the LV apex without a de-
livery introducer sheath. Resheathing, repo-
sitioning, and retrieval of the prosthesis are
possible until the ﬁnal stage of deployment.
PATIENT #1. Patient #1 was a frail, 73-year-
old man with previous myocardial infarction
and stenting who developed severe ischemic cardio-
myopathy and functional MR. He had had multiple
previous admissions for heart failure and remained in
New York Heart Association class IV despite optimal
medical and cardiac resynchronization therapy.
Comorbidities included: chronic renal insufﬁciency,
requiring intermittent hemodialysis; severely im-
paired pulmonary function due to pulmonary ﬁbrosis;
FIGURE 2 Transapical Mitral Valve Implantation Procedure
(A) Advancement of the transapical mitral valve implantation
system across the mitral valve into the left atrium. (B) Full
deployment of the atrial portion of the bioprosthesis in the
left atrium.
TABLE 1 Pre-Operative Echocardiographic Characteristics
of the Patients
LA
Diameter
(mm)
LVEDD
(mm)
Vena
Contracta
(cm)
EROA
(cm2)
MR
Grade LVEF
Patient #1 5.6 76 0.64 0.59 Severe 15%
Patient #2 5.4 62 0.71 0.62 Severe 25%
EROA ¼ effective regurgitant oriﬁce area; LA ¼ left atrium; LVEDD ¼ left
ventricular end-diastolic diameter; LVEF ¼ left ventricular ejection fraction;
MR ¼ mitral regurgitation.
FIGURE 3 Three-Dimensional TEE Conﬁrmation of Coaxial
Position and Correct Orientation of the Mitral Valve
Prosthesis Within the D-Shaped Native Mitral Annulus
TEE ¼ transesophageal echocardiography.
Cheung et al. J A C C V O L . 6 4 , N O . 1 7 , 2 0 1 4
Transapical Mitral Valve Implantation for MR O C T O B E R 2 8 , 2 0 1 4 : 1 8 1 4 – 9
1816systemic hypertension; dyslipidemia; and type 2 dia-
betes. An echocardiogram documented severe LV
dysfunction and dilation. The LV ejection fraction was
15% to 20%, LV end-diasystolic diameter was 76 mm,
and he had an estimated pulmonary arterial systolic
pressure of 60 mm Hg. There was severe functional
MR with restriction of both anterior and posterior
leaﬂets. The calculated Society of Thoracic Surgeons’
risk of mortality for mitral valve replacement was
47.7%, and the Logistic EuroSCORE II was 24.7%.
PATIENT #2. Patient #2 was a 61-year-old woman
with ischemic cardiomyopathy and severe functionalMR secondary to old inferior myocardial infarction.
She had heart failure with New York Heart Associa-
tion classes III to VI symptoms and was referred for
cardiac transplantation. Comorbidities included sys-
temic hypertension, dyslipidemia, chronic obstruc-
tive lung disease, chronic atrial ﬁbrillation, and liver
cirrhosis. Coronary angiography showed a patent
right coronary stent and nonobstructive coronary
atherosclerosis. Echocardiography revealed severe
functional mitral and tricuspid regurgitation with
an LV ejection fraction of 25%, LV end-diasystolic
diameter of 62 mm, and pulmonary hypertension.
Her Society of Thoracic Surgeons’ risk score and
logistic EuroSCORE II were 4.5% and 9.1%, respec-
tively. She was deemed too high risk for surgical
mitral valve replacement and not a good candidate
for the MitraClip secondary to poor coaptation height
by the heart team. Detailed preoperative echocar-
diographic characteristics of both patients are listed
in Table 1.
PRE-OPERATIVE ASSESSMENTS. Cardiac-gated mul-
tislice computed tomography imaging was performed
FIGURE 4 Full Deployment of the Bioprosthesis
and Full Resheathing of the Delivery Catheter
FIGURE 5 TEE Showing a Normally Functioning Mitral Valve Prosthesis
With no Signiﬁcant Paravalvular Leak, a Low Transvalvular Gradient,
and no LV Outﬂow Obstruction
LV ¼ left ventricular; TEE ¼ transesophageal echocardiography.
FIGURE 6 Selective Left Coronary Angiogram Showing
a Patent and Uncompressed Circumﬂex Artery
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1817to delineate mitral valve structures and facilitate
the pre-operative planning of ﬂuoroscopic implant
angles. Both patients were assessed by the multidis-
ciplinary heart team, with a consensus that the risk
with conventional mitral valve surgery was prohibi-
tive. MitraClip was considered as an option for both
patients; however, both patients were believed to be
poor candidates secondary to inadequacy in coapta-
tion depth. Permission to proceed with transcatheter
mitral valve replacement by using the Tiara TAMI
system was granted on compassionate grounds by the
Health Canada Special Access Programme. Informed
consent forms for ﬁrst-in-human implantations were
obtained from both patients.
RESULTS
Procedures were performed in a hybrid operating
room under general anesthesia with endotracheal
intubation. Invasive systemic arterial and pulmonary
arterial monitoring was initiated. Implantations were
performed by a multidisciplinary team consisting of
an interventional cardiologist and a cardiac surgeon,
and were guided by simultaneous transesophageal
echocardiography (TEE) and high-deﬁnition ﬂuoros-
copy. Patients were positioned supine. A 4-cm mini-
anterior thoracotomy was performed to access the
LV apex with the placement of 2 octagonal pledgeted
sutures securing the LV apex. Systemic heparin-
ization was initiated to achieve an activated clotting
time >300 s. Needle puncture of the LV apex was
performed, followed by the introduction of a0.035-inch J-wire across the mitral valve into the left
atrium under TEE and ﬂuoroscopic guidance. A 7-F
sheath was then used to introduce a 0.035-inch
Amplatz extra-stiff wire (Boston Scientiﬁc Corp.,
Marlborough, Massachusetts). The delivery system
was directly inserted into the left ventricle and across
the mitral valve into the mid–left atrium. This action
was followed by release of the atrial portion
(Figures 2A and B). Orientation of the ﬂat portion of the
D-shaped valve to the LVOT, coaxiality, and align-
ment were conﬁrmed with three-dimensional TEE in
the mid–left atrium (Figure 3). After full deployment
of the atrial skirt, the valve was rotated until the ﬂat
portion of the D-shaped frame corresponded with the
LVOT. Seating of the valve onto the atrial annulus
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1818was achieved by gentle traction toward the left
ventricle. Rapid ventricular pacing at 180 beats/min
was initiated, and the ventricular anchoring mecha-
nism was released with capture of the anterior and
posterior native mitral leaﬂets (Figure 4). A post-RATION Implantation of the Transapical Transcatheter
of ﬁrst-in-human cases in high-risk patients with end-stage ischemic
severe mitral regurgitation. (Bottom) Transthoracic echocardiogra-
showing severe mitral regurgitation and at 2 months’ post-
strating a well-seated and functioning mitral prosthesis with no mitral
valvular leak.implant LV angiogram showed no signiﬁcant MR,
and invasive pressure measurement conﬁrmed an
unobstructed LVOT. TEE revealed secure seating
of the prosthesis with normal valvular function,
trivial PVL, and a transvalvular gradient of 2 to 3
mm Hg (Figure 5). Selective left coronary injection
showed a patent and uncompressed circumﬂex artery
(Figure 6). Both patients were hemodynamically sta-
ble throughout the procedure. There were no LV
apical access issues, and blood transfusion was not
required. Patients were extubated in the operating
room and transferred in stable condition to the post-
surgical intensive care unit. An increase in systemic
pressure and a reduction of pulmonary pressure were
evident post-implantation.
Patient #1 was transferred to the ward on day 4 for
convalescence and rehabilitation. On post-operative
day 21, he experienced a post-hemodialysis hypoten-
sive episode requiring cardiopulmonary resuscitation
and reintubation, which was further complicated
by right lower lobe pneumonia and sepsis. The pa-
tient was treated medically, had a remarkable recov-
ery, and was discharged 5 weeks’ post-implant. At
2 months, the patient had recurrent heart failure
requiring readmission. Repeat transthoracic echocar-
diogram conﬁrmed poor LV function with a well-
functioning prosthesis. Despite a well-functioning
prosthesis and elimination of MR, Patient #1 experi-
enced refractory end-stage cardiac failure. Palliative
care was initiated, and the patient died on day 69
post-implant.
Patient #2 had a uneventful recovery and was dis-
charged 5 days’ post-implant. Signiﬁcant symptom-
atic and functional improvements were noted at 2
months, with New York Heart Association functional
class II symptoms, reduction in brain natriuretic
peptide, and improvement in the 6-min walk test.
Repeat transthoracic echocardiograms in both pa-
tients on day 4, and at 1 and 2 months’ post-TAMI
demonstrated normal valve function with no evi-
dence of thrombus formation, PVL, or LVOT obstru-
ction. The transvalvular gradient remained low, at 2
mm Hg (Central Illustration).
STUDY LIMITATIONS. Our study is limited by the low
number of patients and the relatively short follow-up
period. Ongoing compassionate implantation of the
Tiara device and continuing follow-up of the treated
patients will further deﬁne the safety and efﬁcacy of
this procedure.
CONCLUSIONS
MR is the most common valvular pathology. Con-
ventional surgical repair or replacement is used in
PERSPECTIVES
COMPETENCY IN PATIENT CARE: Transcatheter mitral valve
implantation is a less invasive alternative for patients with severe
mitral regurgitation for whom the risks associated with surgical
valve repair or replacement are prohibitive.
TRANSLATIONAL OUTLOOK: More experience with trans-
catheter mitral valve implantation and comparisons of this
technology with intensive medical therapy or surgery in clinical
trials are needed to establish the indications and limitations.
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1819only a small proportion of affected patients. Trans-
catheter valve therapy has revolutionized the man-
agement of aortic stenosis patients and is now
a well-established treatment. The development of
catheter-based therapies for mitral valve disease is
lagging as a consequence of the complexity of mitral
valve anatomy and function.
The Tiara TAMI is a catheter-based mitral implan-
tation system speciﬁcally designed to treat MR. This
valve, with its self-expanding, nitinol alloy–based
frame and bovine pericardial leaﬂets, has speciﬁc
features that accommodate the complex structures
of the mitral valve apparatus. The bioprosthesis is
anatomically shaped, with atrial and ventricular
anchoring mechanisms that secure the prosthesis,
preventing migration, sealing paravalvular leaks, and
allowing unobstructed blood ﬂow across the LVOT.
Capture of the mitral anterior leaﬂet may lower the
risk of LVOT obstruction from the systolic anterior
motion of the anterior leaﬂet. A potential added
beneﬁt of mitral leaﬂet and chordae captures is
preservation of LV geometry, which may promote
reverse remodeling.
Our ﬁrst-in-human cases in 2 high-risk patients
with end-stage ischemic cardiomyopathy and severe
MR demonstrate the feasibility and potential safety
of this procedure. The procedure was performed
without hemodynamic compromise, was minimally
invasive, and off-pump. Instant elimination of MRwith normal valvular function, secure seating, low
transvalvular and LVOT gradient, and the absence of
signiﬁcant PVL were achieved. Ongoing follow-up of
patient clinical status and valvular function con-
tinues. Catheter-based mitral valve implantation is
technically feasible and may present another chapter
in the evolution in the treatment of valvular heart
disease.
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